Transarterial Treatment of Lung Cancer
Purpose: The treatment efficacy of the transarterial approach to lung cancer is evaluated. Materials and Methods: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/7/1078 |
| _version_ | 1797433380084645888 |
|---|---|
| author | Atsushi Hori Ikuo Dejima Shinichi Hori Shuto Oka Tatsuya Nakamura Shota Ueda |
| author_facet | Atsushi Hori Ikuo Dejima Shinichi Hori Shuto Oka Tatsuya Nakamura Shota Ueda |
| author_sort | Atsushi Hori |
| collection | DOAJ |
| description | Purpose: The treatment efficacy of the transarterial approach to lung cancer is evaluated. Materials and Methods: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from the subclavian artery were selected by a microcatheter. Immediately after the selective arterial infusion of anti-neoplastic agents, embolization with a spherical embolic material was carried out. Local tumor effects and overall survival were evaluated. Result: The mean reduction rate was 17.9%, with 24.2% for partial remission and with 2.1% for progression disease. The rate of stable disease was 72.6%. The response rate was 25.3%, and the disease control rate was 97.9%. The median survival time (MST) was 11.4 months, the 1-year survival rate was 45.2%, and the 2-year survival rate was 35.6%. Although it is insignificant, the MST for 51 adenocarcinomas was higher than that of 29 squamous cell carcinomas (18.6 months and 9.4 months, respectively). The local extension of tumors related to a better prognosis, though it was not significant. Lymph node metastases and distant metastases were poor prognostic factors. No major complications nor treatment-related mortalities were found in this study. Conclusion: The transarterial treatment for lung cancer should be considered as a treatment option when the other treatments were not indicated both in initial cases and in recurrent cases. |
| first_indexed | 2024-03-09T10:16:12Z |
| format | Article |
| id | doaj.art-37ac9512704f40478ee7b1c80c3e2c96 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T10:16:12Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-37ac9512704f40478ee7b1c80c3e2c962023-12-01T22:22:03ZengMDPI AGLife2075-17292022-07-01127107810.3390/life12071078Transarterial Treatment of Lung CancerAtsushi Hori0Ikuo Dejima1Shinichi Hori2Shuto Oka3Tatsuya Nakamura4Shota Ueda5Institute for Image Guided Therapy, Izumisano 598-0047, JapanDepartment of Radiology, Wakayama Medical University, Wakayama 641-8509, JapanInstitute for Image Guided Therapy, Izumisano 598-0047, JapanInstitute for Image Guided Therapy, Izumisano 598-0047, JapanInstitute for Image Guided Therapy, Izumisano 598-0047, JapanDepartment of Radiology, Wakayama Medical University, Wakayama 641-8509, JapanPurpose: The treatment efficacy of the transarterial approach to lung cancer is evaluated. Materials and Methods: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from the subclavian artery were selected by a microcatheter. Immediately after the selective arterial infusion of anti-neoplastic agents, embolization with a spherical embolic material was carried out. Local tumor effects and overall survival were evaluated. Result: The mean reduction rate was 17.9%, with 24.2% for partial remission and with 2.1% for progression disease. The rate of stable disease was 72.6%. The response rate was 25.3%, and the disease control rate was 97.9%. The median survival time (MST) was 11.4 months, the 1-year survival rate was 45.2%, and the 2-year survival rate was 35.6%. Although it is insignificant, the MST for 51 adenocarcinomas was higher than that of 29 squamous cell carcinomas (18.6 months and 9.4 months, respectively). The local extension of tumors related to a better prognosis, though it was not significant. Lymph node metastases and distant metastases were poor prognostic factors. No major complications nor treatment-related mortalities were found in this study. Conclusion: The transarterial treatment for lung cancer should be considered as a treatment option when the other treatments were not indicated both in initial cases and in recurrent cases.https://www.mdpi.com/2075-1729/12/7/1078lung cancerbronchial arteryantineoplastic agentsembolic materialmicrocatheter |
| spellingShingle | Atsushi Hori Ikuo Dejima Shinichi Hori Shuto Oka Tatsuya Nakamura Shota Ueda Transarterial Treatment of Lung Cancer Life lung cancer bronchial artery antineoplastic agents embolic material microcatheter |
| title | Transarterial Treatment of Lung Cancer |
| title_full | Transarterial Treatment of Lung Cancer |
| title_fullStr | Transarterial Treatment of Lung Cancer |
| title_full_unstemmed | Transarterial Treatment of Lung Cancer |
| title_short | Transarterial Treatment of Lung Cancer |
| title_sort | transarterial treatment of lung cancer |
| topic | lung cancer bronchial artery antineoplastic agents embolic material microcatheter |
| url | https://www.mdpi.com/2075-1729/12/7/1078 |
| work_keys_str_mv | AT atsushihori transarterialtreatmentoflungcancer AT ikuodejima transarterialtreatmentoflungcancer AT shinichihori transarterialtreatmentoflungcancer AT shutooka transarterialtreatmentoflungcancer AT tatsuyanakamura transarterialtreatmentoflungcancer AT shotaueda transarterialtreatmentoflungcancer |